Bamlanivimab and Etesevimab

Active ingredient description

Bamlanivimab is a recombinant neutralizing human IgG1K monoclonal antibody (mAb) to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. Etesevimab is a recombinant neutralizing human IgG1K mAb to the spike protein of SARS-CoV-2, with amino acid substitutions in the Fc region (L234A, L235A) to reduce effector function. Bamlanivimab and etesevimab bind to different but overlapping epitopes in the receptor binding domain (RBD) of the S-protein. Using both antibodies together is expected to reduce the risk of viral resistance.

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US